JP7317866B2 - オキサボリニン環を含む新規ベンズイミドアミド化合物 - Google Patents

オキサボリニン環を含む新規ベンズイミドアミド化合物 Download PDF

Info

Publication number
JP7317866B2
JP7317866B2 JP2020567854A JP2020567854A JP7317866B2 JP 7317866 B2 JP7317866 B2 JP 7317866B2 JP 2020567854 A JP2020567854 A JP 2020567854A JP 2020567854 A JP2020567854 A JP 2020567854A JP 7317866 B2 JP7317866 B2 JP 7317866B2
Authority
JP
Japan
Prior art keywords
compound
benzo
dihydro
hydroxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567854A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019234075A5 (https=
JP2021530440A (ja
JP2021530440A5 (https=
Inventor
リドル，ジョン
ウォーカー，アン・ルイーズ
ホワイト，ジェンマ・ヴィクトリア
ドゥニ，アレクシ
ドディク，ネリーナ
フーシェ，マリー－エレーヌ
ブイヨ，アン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2021530440A publication Critical patent/JP2021530440A/ja
Publication of JPWO2019234075A5 publication Critical patent/JPWO2019234075A5/ja
Publication of JP2021530440A5 publication Critical patent/JP2021530440A5/ja
Application granted granted Critical
Publication of JP7317866B2 publication Critical patent/JP7317866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020567854A 2018-06-07 2019-06-05 オキサボリニン環を含む新規ベンズイミドアミド化合物 Active JP7317866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1809378.1A GB201809378D0 (en) 2018-06-07 2018-06-07 Novel compounds
GB1809378.1 2018-06-07
PCT/EP2019/064599 WO2019234075A1 (en) 2018-06-07 2019-06-05 Novel benzimidamides compounds comprising an oxaborinin ring

Publications (4)

Publication Number Publication Date
JP2021530440A JP2021530440A (ja) 2021-11-11
JPWO2019234075A5 JPWO2019234075A5 (https=) 2022-06-09
JP2021530440A5 JP2021530440A5 (https=) 2022-06-09
JP7317866B2 true JP7317866B2 (ja) 2023-07-31

Family

ID=62975712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567854A Active JP7317866B2 (ja) 2018-06-07 2019-06-05 オキサボリニン環を含む新規ベンズイミドアミド化合物

Country Status (9)

Country Link
US (2) US11352372B2 (https=)
EP (1) EP3802550B1 (https=)
JP (1) JP7317866B2 (https=)
KR (1) KR102661802B1 (https=)
CN (2) CN112236433B (https=)
BR (1) BR112020024740A2 (https=)
ES (1) ES2973710T3 (https=)
GB (1) GB201809378D0 (https=)
WO (1) WO2019234075A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
PE20221906A1 (es) 2019-09-18 2022-12-23 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535781A (ja) 2005-02-16 2008-09-04 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
WO2009071601A1 (en) 2007-12-03 2009-06-11 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
JP2017505299A (ja) 2014-01-23 2017-02-16 シクセラ ファーマ エービー 新しいカリクレイン７阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014927A (zh) * 2008-03-06 2011-04-13 安纳考尔医药公司 作为抗炎药的含硼的小分子
DK3097085T3 (da) 2014-01-23 2020-10-26 Sixera Pharma Ab Benzoxazinonderivater til behandling af hudsygdomme
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535781A (ja) 2005-02-16 2008-09-04 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
WO2009071601A1 (en) 2007-12-03 2009-06-11 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
JP2017505299A (ja) 2014-01-23 2017-02-16 シクセラ ファーマ エービー 新しいカリクレイン７阻害剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Alessio Nocentini et al.，Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018)，Expert Opinion on Therapeutic Patents，2018年05月11日，Volume 28, Issue 6，pp. 493-504
Ann L. Walker et al.，Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors，Bioorganic & Medicinal Chemistry Letters，2019年09月07日，Volume 29, Issue 20
Nicolas Masurier et al.，Inhibitors of Kallikrein-related peptidases: An overview，Medicinal Research Reviews，2017年06月13日，Volume 38, Issue 2，pp. 655-683

Also Published As

Publication number Publication date
BR112020024740A2 (pt) 2021-03-23
WO2019234075A1 (en) 2019-12-12
US20220267357A1 (en) 2022-08-25
US11767333B2 (en) 2023-09-26
EP3802550A1 (en) 2021-04-14
GB201809378D0 (en) 2018-07-25
CN112236433B (zh) 2023-04-04
US20210253604A1 (en) 2021-08-19
JP2021530440A (ja) 2021-11-11
CN116217603A (zh) 2023-06-06
US11352372B2 (en) 2022-06-07
KR20210018464A (ko) 2021-02-17
ES2973710T3 (es) 2024-06-24
EP3802550B1 (en) 2023-12-27
KR102661802B1 (ko) 2024-04-26
CN112236433A (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
KR101368988B1 (ko) 디펩티딜 펩티다제 억제제
JP4110324B2 (ja) 新規インダゾール誘導体
EP3472165B1 (en) N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
US11724989B2 (en) MCT4 inhibitors for treating disease
CN106518845B (zh) 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
JP6787998B2 (ja) 置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法
KR20090026264A (ko) 측쇄에 스피로 고리 구조를 갖는 신규 인다졸 유도체
US11767333B2 (en) Benzimidamides compounds comprising an oxaborinin ring
KR20200013718A (ko) 바닌 억제제로서의 헤테로방향족 화합물
EP3417850A1 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
KR20160006207A (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
JP2017533245A (ja) Ｂａｃｅ１阻害剤としての２−アミノ−６−（ジフルオロメチル）−５，５−ジフルオロ−６−フェニル−３，４，５，６−テトラヒドロピリジン
JP2021535154A (ja) バニン阻害剤としてのヘテロ芳香族化合物
HU201061B (en) Process for producing new dihydropyridine derivatives
HUP0302405A2 (hu) Új benzofuránszármazékok
EP4229055B1 (en) Compounds and compositions for the treatment of cryptosporidiosis
WO2007025776A2 (en) Cysteine protease inhibitors
HK40055452A (en) Heteroaryl inhibitors of pde4
HK40066026A (en) Mct4 inhibitors for treating disease
HK40055452B (en) Heteroaryl inhibitors of pde4
TW201920144A (zh) 環丁基-咪唑啶酮化合物
JPWO2000059913A1 (ja) 新規チアゾロベンゾイミダゾール誘導体
HK1253239B (en) Mct4 inhibitors for treating disease
JPWO2001030771A1 (ja) チアゾリジンジオン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220601

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230719

R150 Certificate of patent or registration of utility model

Ref document number: 7317866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150